According to the SURMOUNT clinical trial program, participants experienced weight reductions ranging from 16% to 22.5% over 72 weeks depending on dosage strength
Secondary Research 2.3
Results A total of 11 studies were included in this meta-analysis, including 6 studies on GLP-1 RA, 1 study on GLP-1 and GIP dual receptor agonists, 1 study on orlistat, 2 studies on phentermine-topiramate, and 1 study on naltrexone-bupropion (Additional file 1: Table S2) [22,23,24,25,26,27,28,29,30,31,32]
This reflects different appetites for control: Roche saw petrelintide as one piece, not a platform acquisition
Van Hove, A
However, darker pigmentation does not equal complete photoprotection